Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Long-term experience using high-dose stereotactic body radiotherapy (SBRT) confirms that this highly focused, rigidly delivered, and tightly controlled radiation approach results in excellent local ...

Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer Survival outcomes were similar, but ...

Stereotactic body radiotherapy (SBRT) is a safe treatment option for patients with oligometastatic cancer, with only 0.5% of patients experiencing severe acute toxicities within 6 months, according to ...

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer The article by Grills ...

SBRT and hypofractionated CRT showed similar effectiveness and low severe side effects in stage 1 NSCLC treatment. SBRT delivers higher radiation doses in fewer sessions, while hypofractionated CRT ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Please provide your email address to receive an email when new articles are posted on . The number of facilities prescribing single-fraction lung SBRT is gradually growing, yet primarily at ...